OncLiveDr. Plimack on the Growth of Immunotherapy in Bladder CancerOncLiveElizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the growth of immunotherapy for the treatment of patients with bladder ca… Continue reading
Solid Biosciences reveals upgraded clinical hold for gene therapyBioPharma DiveSolid Biosciences Inc. announced that the Food and Drug Administration has placed its Phase 1/2 Duchenne Muscular Dystrophy (DMD) trial on full clinical hold weeks after the… Continue reading
OncLiveExpert Highlights Immunotherapy Success in GU CancersOncLiveThe landscape of genitourinary (GU) malignancies is rapidly evolving, with promising immunotherapy breakthroughs in renal cell carcinoma (RCC) and urothelial carcinoma. The phase III ra… Continue reading
Science Daily |
Clearing clumps of protein in aging neural stem cells boosts their activity
Science Daily As the cells age, they become less proficient at disposing of these protein aggregates, and their ability to respond readily to “make new neurons” signals wanes. Restoring the ability of the lysosomes to function normally rejuvenates the cells’ ability … Aging neural stem cells struggle to take out the trash, say Stanford researchersScope (blog) |
San Francisco Chronicle |
Cancer immunotherapy company Arcus Biosciences up 14% in IPO
San Francisco Chronicle Arcus Biosciences Founder and CEO Terry Rosen, right, is applauded as he rings a ceremonial bell when his company’s IPO begins trading on the floor of the New York Stock Exchange, Thursday, March 15, 2018. (AP Photo/Richard Drew). Arcus Biosciences … |
FierceBiotech |
Arbor Biotechnologies comes out of stealth with new CRISPR enzyme
FierceBiotech The company announced its first scientific findings of a new enzyme, Cas13d, a CRISPR-Cas13 enzyme that could offer advantages over other enzymes, including its small size, allowing easier packaging into the viruses used to deliver CRISPR. It was found … UPDATED: CRISPR pioneer Feng Zhang co-founds a ‘limitless’ biotech upstart with big plans for speeding new drug …Endpoints News Why CRISPR Therapeutics Slipped 10% on ThursdayMotley Fool CRISPR genetic editing takes another big step forward, targeting RNAScience Daily STAT –Boston Business Journal all 10 news articles » |